$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000112623418000123 Filed on August 06, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$120.0K	$2.252M	$10.37M
YoY Change	-97.81%	-78.28%	415.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.800M	$7.900M	$8.900M
YoY Change	-13.92%	-11.24%	3.49%
% of Gross Profit
Research & Development	$7.570M	$12.09M	$18.20M
YoY Change	-59.04%	-33.58%	-33.6%
% of Gross Profit
Depreciation & Amortization	$300.0K	$300.0K	$300.0K
YoY Change	-25.0%	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$15.16M	$20.00M	$27.10M
YoY Change	-42.56%	-26.19%	-25.84%
Operating Profit	-$15.04M	-$17.75M	-$16.73M
YoY Change	-28.07%	6.1%	-51.56%
Interest Expense	$2.000K	$36.00K	$7.000K
YoY Change	-33.33%	414.29%	16.67%
% of Operating Profit
Other Income/Expense, Net	$644.0K	$435.0K	$1.000K
YoY Change	302.5%	43400.0%	-98.33%
Pretax Income	-$14.39M	-$17.31M	-$16.73M
YoY Change	-30.61%	3.51%	-51.47%
Income Tax	-$7.000M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.403M	-$17.31M	-$16.73M
YoY Change	-64.11%	3.51%	-48.36%
Net Earnings / Revenue	-6169.17%	-768.78%	-161.29%
Basic Earnings Per Share	-$0.20	-$0.47	-$0.57
Diluted Earnings Per Share	-$1.805M	-$4.220M	-$5.219M
COMMON SHARES
Basic Shares Outstanding	37.21M shares		29.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$122.1M	$137.1M	$107.8M
YoY Change	1.16%	27.18%	-32.83%
Cash & Equivalents	$122.1M	$137.1M	$107.8M
Short-Term Investments
Other Short-Term Assets	$4.900M	$5.200M	$4.900M
YoY Change	81.48%	6.12%	22.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$700.0K	$817.0K	$11.26M
Total Short-Term Assets	$135.1M	$143.5M	$130.2M
YoY Change	0.66%	10.17%	-24.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.096M	$4.387M	$5.886M
YoY Change	-25.89%	-25.47%	-20.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.236M	$4.527M	$5.886M
YoY Change	-23.36%	-23.09%	-20.83%
TOTAL ASSETS
Total Short-Term Assets	$135.1M	$143.5M	$130.2M
Total Long-Term Assets	$4.236M	$4.527M	$5.886M
Total Assets	$139.3M	$148.0M	$136.1M
YoY Change	-0.29%	8.73%	-24.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.238M	$7.334M	$11.37M
YoY Change	-89.56%	-35.49%	516.87%
Accrued Expenses	$8.736M	$8.527M	$14.45M
YoY Change	-36.84%	-41.0%	-26.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%	-50.0%	0.0%
Total Short-Term Liabilities	$10.13M	$16.04M	$26.30M
YoY Change	-61.17%	-39.01%	16.67%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$100.0K	$200.0K
YoY Change	0.0%	-50.0%	-50.0%
Other Long-Term Liabilities	$6.900M	$7.000M	$7.000M
YoY Change	-1.43%	0.0%	-2.78%
Total Long-Term Liabilities	$6.988M	$7.026M	$7.218M
YoY Change	-2.39%	-2.66%	-4.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.13M	$16.04M	$26.30M
Total Long-Term Liabilities	$6.988M	$7.026M	$7.218M
Total Liabilities	$17.12M	$23.07M	$33.52M
YoY Change	-48.51%	-31.19%	11.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$280.4M	-$273.0M	-$203.1M
YoY Change	25.32%	34.41%	48.87%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.409M	$1.405M	$1.098M
YoY Change	26.59%	27.96%	40.05%
Treasury Stock Shares	88.73K shares	87.65K shares	53.43K shares
Shareholders Equity	$122.2M	$124.9M	$102.6M
YoY Change
Total Liabilities & Shareholders Equity	$139.3M	$148.0M	$136.1M
YoY Change	-0.29%	8.73%	-24.14%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$7.403M	-$17.31M	-$16.73M
YoY Change	-64.11%	3.51%	-48.36%
Depreciation, Depletion And Amortization	$300.0K	$300.0K	$300.0K
YoY Change	-25.0%	0.0%	-50.0%
Cash From Operating Activities	-$15.00M	-$6.900M	-$10.90M
YoY Change	108.33%	-36.7%	-32.72%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$100.0K
YoY Change	-100.0%	-100.0%	-94.12%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$200.0K
YoY Change		-100.0%	-80.0%
Cash From Investing Activities	$0.00	$0.00	$100.0K
YoY Change		-100.0%	-114.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	100.0K	300.0K
YoY Change	-100.0%	-66.67%	-25.0%
NET CHANGE
Cash From Operating Activities	-15.00M	-6.900M	-10.90M
Cash From Investing Activities	0.000	0.000	100.0K
Cash From Financing Activities	0.000	100.0K	300.0K
Net Change In Cash	-15.00M	-6.800M	-10.50M
YoY Change	-217.19%	-35.24%	-36.36%
FREE CASH FLOW
Cash From Operating Activities	-$15.00M	-$6.900M	-$10.90M
Capital Expenditures	$0.00	$0.00	-$100.0K
Free Cash Flow	-$15.00M	-$6.900M	-$10.80M
YoY Change	105.48%	-36.11%	-25.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37214286	shares
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37214286	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37285745	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37168122	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37198100	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37109556	shares
CY2018Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	87645	shares
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	58566	shares
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37214286	shares
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37214286	shares
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137066000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5243000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6226000	USD
CY2018Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	360000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	175466000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4387000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5091000	USD
CY2018Q2	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	140000	USD
CY2017Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	140000	USD
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5231000	USD
CY2018Q2	us-gaap	Assets Assets	148013000	USD
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158708000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	356000	USD
CY2018Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	817000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	10176000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	143486000	USD
CY2018Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	4527000	USD
CY2017Q4	us-gaap	Assets Assets	180697000	USD
CY2017Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7109000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	23067000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	29140000	USD
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1142000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7334000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9256000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8527000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12467000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	56000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	87000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	87000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	92000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	92000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	93000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	160000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16041000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22031000	USD
CY2018Q2	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	74000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	111000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	952000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	998000	USD
CY2018Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7026000	USD
CY2018Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2018Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	373000	USD
CY2017Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	372000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399018000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	389786000	USD
CY2018Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1405000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237459000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	124946000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	151557000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	148013000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180697000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	11268000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	12900000	USD
	us-gaap	Licenses Revenue LicensesRevenue	884000	USD
	us-gaap	Licenses Revenue LicensesRevenue	231000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	12152000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	13131000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32402000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33925000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16204000	USD
	us-gaap	Operating Expenses OperatingExpenses	51056000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36454000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37925000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-113000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	846000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	202000	USD
	us-gaap	Interest Expense InterestExpense	49000	USD
	us-gaap	Interest Expense InterestExpense	113000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	831000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35623000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37949000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-310000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37639000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	151557000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8997000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	106000	USD
	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	42000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	124946000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37639000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8997000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273040000	USD
CY2018Q2	us-gaap	Revenue From Grants RevenueFromGrants	1884000	USD
CY2017Q2	us-gaap	Revenue From Grants RevenueFromGrants	10314000	USD
CY2018Q2	us-gaap	Licenses Revenue LicensesRevenue	368000	USD
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue	56000	USD
CY2018Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2252000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	10370000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12088000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18200000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7912000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8897000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17131000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	20000000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	27097000	USD
	us-gaap	Operating Expenses OperatingExpenses	48606000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17748000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16727000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-519000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1005000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-9865000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-13268000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5862000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11356000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-4000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-312000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-56000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-224000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	51000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21612000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23914000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	108000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	172000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	101000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	115000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	236000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	453000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	263000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	245000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	104000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	122000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-131000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-109000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	461000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	117000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	36000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	7000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	435000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17313000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16726000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-17313000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-16726000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23713000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158708000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131490000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137066000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107777000	USD
	us-gaap	Interest Paid InterestPaid	5000	USD
	us-gaap	Interest Paid InterestPaid	8000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	14000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </span></div><div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The accompanying condensed consolidated financial statements as of June 30, 2018 and for the three and six months ended have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of $37.6 million from its inital public offering in 2011, completed a follow-on offering of its common stock raising net proceeds of $49.0 million in 2013, and raised an additional $58.7 million in net proceeds from an at the market (ATM) offering completed in 2015. </span></div><div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">During 2017, the Company sold 1,940,656 shares of its common stock under an ATM offering, with aggregate net proceeds of $19.3 million after commissions of $398,000 paid to Cantor Fitzgerald & Co. (Cantor) as the placement agent, and other costs of $163,000. In October 2017, the Company sold 5,750,000 of its shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. On March 12, 2018, the Company entered into a new Sales Agreement with Cantor under which the Company may sell up to $60.0 million of its common stock in one or more placements at prevailing market prices in an ATM offering (the 2018 ATM Offering). As of June 30, 2018, no shares have been sold under the 2018 ATM Offering. </span></div><div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The Company's cash and cash equivalents as of June 30, 2018 are expected to be adequate to satisfy the Company's liquidity requirements into the second half of 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:13pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;vertical-align:bottom;">Use of Estimates</span></div><div style="text-indent:24pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	167000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	271000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6900000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6600000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37165529	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29225386	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37160334	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29219469	shares
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	130000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	263000	USD
	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	42000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10568000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	637000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	707000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	34000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-113000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	44000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-21642000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-9865000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21612000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-310000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37639000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2017Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.50
CY2017	us-gaap	Restructuring Charges RestructuringCharges	1700000	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	207000	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	207000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="text-indent:22pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.</span></div><div style="text-indent:22pt;line-height:120%;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div>
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5762000	USD
CY2018Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	10682000	USD
CY2018Q1	us-gaap	Assets Assets	180739000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237417000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180739000	USD
CY2018Q2	us-gaap	Revenue From Grants RevenueFromGrants	1884000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	11268000	USD
CY2018Q2	us-gaap	Licenses Revenue LicensesRevenue	368000	USD
	us-gaap	Licenses Revenue LicensesRevenue	884000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12088000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32402000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-17313000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35623000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-519000	USD
CY2018Q2	us-gaap	Government Contract Receivable GovernmentContractReceivable	406000	USD
CY2017Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	9300000	USD
CY2018Q2	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	25000	USD
CY2017Q4	nlnk	Government Contract Accrued Subcontractor Fees GovernmentContractAccruedSubcontractorFees	1800000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4200000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4600000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000000.0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10600000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	nlnk	Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit	-140000	USD
CY2018Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	653000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-17313000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-16726000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37165529	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29225386	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37160334	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29219469	shares
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57

Files In Submission

Name	View Source	Status
0001126234-18-000123-index-headers.html	Edgar Link	pending
0001126234-18-000123-index.html	Edgar Link	pending
0001126234-18-000123.txt	Edgar Link	pending
0001126234-18-000123-xbrl.zip	Edgar Link	pending
a2018630-10qxex101.htm	Edgar Link	pending
a2018630-10qxex311.htm	Edgar Link	pending
a2018630-10qxex312.htm	Edgar Link	pending
a2018630-10qxex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlnk-20180630.htm	Edgar Link	pending
nlnk-20180630.xsd	Edgar Link	pending
nlnk-20180630_cal.xml	Edgar Link	unprocessable
nlnk-20180630_def.xml	Edgar Link	unprocessable
nlnk-20180630_g1.jpg	Edgar Link	pending
nlnk-20180630_htm.xml	Edgar Link	completed
nlnk-20180630_lab.xml	Edgar Link	unprocessable
nlnk-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2018 Q3 Form 10-Q Financial Statement

#000112623418000123 Filed on August 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2018 Q3 Form 10-Q Financial Statement

#000112623418000123 Filed on August 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo